Relationship of DcR3 expression with Fas expression in patients with chronic hepatitis B,liver cirrhosis and liver cancer

doi:10.3969/j.issn.1673-8640.2017.03.005

Abstract

Abstract:

Objective To investigate the expression of serum decoy receptor 3 （DcR3） in patients with chronic hepatitis B,liver cirrhosis and liver cancer and its relationship with Fas expression. Methods Alanine aminotransferase （ALT）and hepatitis B virus（HBV） DNA load were determined in 34 patients with chronic hepatitis B,31 patients with liver cirrhosis,28 patients with liver cancer and 28 healthy subjects （healthy control group）. A total of 10 of the patients underwent liver tissue pathological examination. Serum DcR3 levels were determined by enzyme-linked immunosorbent assay （ELISA）,and the correlations of serum DcR3 levels with ALT and HBV DNA load were analyzed. The levels of serum DcR3 and Fas mRNA in liver tissue were determined by fluorescence quantitation polymerase chain reaction （PCR）,and the correlation analysis was performed. Results Compared with healthy control group,serum DcR3 levels in 3 patient groups all increased （P<0.05）. Serum DcR3 levels became higher in liver cancer group than the other 2 patient groups（P<0.05）. There was no statistical significance between chronic hepatitis B and liver cirrhosis groups（P>0.05）. Serum DcR3 levels were correlated with ALT and HBV DNA load（r=0.448 1 and 0.500 7,P<0.05）. The expression of Fas mRNA decreased in liver tissue in liver cancer group（P<0.05）. There was a negative correlation between the expressions of serum DcR3 and Fas mRNA（r=-0.794 1,P<0.05）. Conclusions DcR3 affects the development of HBV-related liver cancer through Fas .

Key words: Decoy receptor 3, Fas receptor, Chronic hepatitis B, Liver cirrhosis, Liver cancer

CLC Number:

R446.62

LIANG Dongyu, HOU Yanqiang, LOU Xiaoli. Relationship of DcR3 expression with Fas expression in patients with chronic hepatitis B,liver cirrhosis and liver cancer[J]. Laboratory Medicine, 2017, 32(3): 178-181.

Figures/Tables 4

References 12

[1]	CHAN S L,WONG V W,QIN S,et al.Infection and cancer:the case of hepatitis B[J]. J Clin Oncol,2016,34(1):83-90.
[2]	HUNG S C,HSU T W,LIN Y P,et al.Decoy receptor 3,a novel inflammatory marker, and mortality in hemodialysis patients[J]. Clin J Am Soc Nephrol,2012,7(8):1257-1265.
[3]	CHEN G,LUO D.Expression of decoy receptor 3 in liver tissue microarrays[J]. Natl Med J India,2008,21(6):275-278.
[4]	ZHAN C,PATSKOYSKY Y,YAN Q, et al.Decoy strategies:the structure of TL1A:DcR3 complex[J]. Structure,2011,19(2):162-171.
[5]	ZHOU J,SONG S,HE S,et al.Silencing of decoy receptor 3 (DcR3) expression by siRNA in pancreatic carcinoma cells induces Fas ligand-mediated apoptosis in vitro and in vivo[J]. Int J Mol Med,2013,32(3):653-660.
[6]	GILL R M,HUNT J S.Soluble receptor (DcR3) and cellular inhibitor of apoptosis-2 (cIAP-2) protect human cytotrophoblast cells against LIGHT-mediated apoptosis[J]. Am J Pathol,2004,165(1):309-317.
[7]	LEI J H,HE X E,YANG X,et al.Effects of HBV X gene and arsenic trioxide on the expression of p53 in cultured HepG2 cells[J]. Chin Med J (Engl),2007,120(24):2181-2184.
[8]	XIA L,TIAN D,HUANG W,et al.Upregulation of IL-23 expression in patients with chronic hepatitis B is mediated by the HBx/ERK/NF-κB pathway[J]. J Immunol,2012,188(2):753-764.
[9]	SHI Z,JIAO S,ZHOU Z.STRIPAK complexes in cell signaling and cancer[J]. Oncogene,2016,35(35):4549-4557.
[10]	何建方,周建方,戴利成,等. 慢性乙型肝炎患者治疗前后血清sFas和sFasL的变化及其临床意义[J]. 检验医学,2005,20(1):20-22.
[11]	吴潇. Fas抗原在肠癌组织中的表达[J]. 检验医学,2005,20(3):260-261.
[12]	KYKALOS S,MATHAIOU S,KARAYIANNAKIS A J,et al.Tissue expression of the proteins fas and fas ligand in colorectal cancer and liver metastases[J]. J Gastrointest Cancer,2012,43(2):224-228.

[1]	GU Yi, WANG Rui, DENG Jie, YANG Yijing, ZHOU Wangke, CHEN Yunuo, CHEN Xiaosong, SHEN Wei, ZHOU Jingyi. Differential analysis and prognostic diagnostic value of inflammatory biomarkers in liver transplantation in patients with severe hepatitis and cirrhosis [J]. Laboratory Medicine, 2023, 38(11): 1044-1051.
[2]	JI Ye, YUAN Xiaosun, ZHANG Lei, MA Huili, XUE Yongfei, LI Changsheng, ZHANG Jingwei, REN Zhonghai, ZHANG Tengfei. Expression of lncRNA HULC in papillary thyroid carcinoma tissues [J]. Laboratory Medicine, 2022, 37(7): 605-609.
[3]	LIU Yang, GENG Kunjing, LI Hongjiang, SHI Haoxi, CHEN Sisi. Relationship of 25（OH）D₃ and liver inflammatory stage with the efficacy of antiviral therapy [J]. Laboratory Medicine, 2022, 37(7): 628-631.
[4]	WU Sujun, JI Hengtao, PENG Mengle. Clinical values of IL-18,IL-37,NLRP3 and NK/DC ratio in hepatitis B-related liver cirrhosis [J]. Laboratory Medicine, 2022, 37(6): 518-523.
[5]	MA Yanting, SU Xi, HUANG Fei, WANG Mengxian, SHEN Minna, ZHANG Chunyan, WANG Beili, PAN Baishen, GUO Wei. Clinical role of HBV RNA detection in chronic hepatitis B [J]. Laboratory Medicine, 2022, 37(1): 72-77.
[6]	LI Caidong, ZHANG Xuqiang, LEI Zhiping, CHEN Qiaoli, CHEN Lu, TIAN Pengfei, DUAN Zhengjun. Clinical values of IL-1β,IL-6 and TNF-α in different clinical courses of chronic HBV infection [J]. Laboratory Medicine, 2021, 36(8): 790-794.
[7]	LIU Tingting, LIN Yuting, Mila , LI Xiaoqin. Correlation between serum IL-33 level and its gene polymorphism and the clinical outcome of HBV infection [J]. Laboratory Medicine, 2021, 36(11): 1101-1105.
[8]	BIE Lihan, FANG Meng, FENG Huijuan, LU Zhicheng, GAO Chunfang. Role of sialylated haptoglobin for the auxiliary diagnosis of hepatitis B-related hepatocellular carcinoma [J]. Laboratory Medicine, 2020, 35(11): 1147-1152.
[9]	GUO Ping, ZHUANG Lihua, CHEN Liting, WANG Jianbiao, WU Jianfeng. Roles of MCV,RDW and SAA in the progression of chronic hepatitis B [J]. Laboratory Medicine, 2020, 35(11): 1153-1157.
[10]	WANG Yingzhi, LIU Hua, WANG Wenjuan, GAO Feng, YANG Cuixia. Roles of serum microRNA-122 and microRNA-155 in patients with chronic hepatitis B [J]. Laboratory Medicine, 2019, 34(8): 691-695.
[11]	XIAO Xiao, GAO Chunfang. Research and application progress of circulating tumor cells in primary liver cancer [J]. Laboratory Medicine, 2019, 34(7): 661-666.
[12]	YU Xiaochun, HU Xujiao, ZHANG Jiaqing, GUO Leilei. Roles of HA,Ⅳ-C,APRI and Fib-4 in the diagnosis of hepatitis B-related liver fibrosis [J]. Laboratory Medicine, 2019, 34(6): 539-542.
[13]	GAO Wanqin, ZHANG Qin, ZHU Lin, WU Bin, HE Wentao, ZHANG Tinglu, ZHAO Changxin. Analysis of genotyping and 6 nucleosides' resistance of HBV in patients with chronic hepatitis B [J]. Laboratory Medicine, 2019, 34(11): 994-997.
[14]	KANG Haiyan, HAO Ruofei, REN Ciju. Relationship between angiotensin Ⅱ level and the severity of liver cirrhosis [J]. Laboratory Medicine, 2018, 33(12): 1112-1115.
[15]	HOU Li, YU Lu, NIU Yao, ZHANG Yuan, WANG Liang. Role of noninvasive diagnostic model for liver fibrosis in patients with chronic hepatitis B [J]. Laboratory Medicine, 2018, 33(10): 888-893.